DermTech Financials

DMTK Stock  USD 0.71  0.06  9.23%   
Based on the key indicators obtained from DermTech's historical financial statements, DermTech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, DermTech's Long Term Debt is quite stable compared to the past year. Cash And Short Term Investments is expected to rise to about 152.3 M this year, although the value of Retained Earnings are projected to rise to (402.7 M). Key indicators impacting DermTech's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.40.38
Notably Up
Slightly volatile
Current Ratio6.447.83
Significantly Down
Slightly volatile
The financial analysis of DermTech is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for DermTech includes many different criteria found on its balance sheet. For example, investors should never minimize DermTech's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor DermTech's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in DermTech.

Net Income

(95.84 Million)

With this module, you can analyze DermTech financials for your investing period. You should be able to track the changes in DermTech individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past DermTech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DermTech's financial statements are interrelated, with each one affecting the others. For example, an increase in DermTech's assets may result in an increase in income on the income statement.
Evaluating DermTech's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of DermTech's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the DermTech's relative financial performance

Chance Of Distress

Over 81

 
100  
 
Zero
Very High
DermTech has more than 81 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for DermTech stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, DermTech's odds of distress score SHOULD NOT be confused with the real chance of DermTech filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as DermTech is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include DermTech's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in DermTech's official financial statements usually reflect DermTech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DermTech. For example, before you start analyzing numbers published by DermTech accountants, it's critical to develop an understanding of what DermTech's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of DermTech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DermTech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DermTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DermTech. Please utilize our Beneish M Score to check the likelihood of DermTech's management manipulating its earnings.

DermTech Company Summary

DermTech competes with Advanced Micro, Uber Technologies, MACOM Technology, Arrow Electronics, and NETGEAR. DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS24984K1051
CUSIP24984K105 G2379F108 G2379F124
LocationCalifornia; U.S.A
Business Address12340 El Camino
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.dermtech.com
Phone858 450 4222
CurrencyUSD - US Dollar
You should never invest in DermTech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of DermTech Stock, because this is throwing your money away. Analyzing the key information contained in DermTech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

DermTech Key Financial Ratios

Generally speaking, DermTech's financial ratios allow both analysts and investors to convert raw data from DermTech's financial statements into concise, actionable information that can be used to evaluate the performance of DermTech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that DermTech reports annually and quarterly.

DermTech Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets18.2M69.8M248.3M202.1M121.9M82.3M
Other Current Liab2.7M2.8M6.3M11.4M13.1M13.7M
Net Tangible Assets12.5M63.5M229.7M132.4M152.2M159.8M
Retained Earnings(91.1M)(126.4M)(206.4M)(323.0M)(423.9M)(402.7M)
Accounts Payable1.6M1.6M2.9M2.4M1.5M1.2M
Cash15.4M24.2M176.9M77.8M36.7M33.4M
Other Assets84K167K3.2M3.7M4.2M4.4M
Capital Surpluse103.6M189.8M436.2M456.2M524.6M550.8M
Inventory35K104K480K1.8M1.0M1.1M
Other Current Assets1.1M1.5M3.2M3.9M581K1.1M
Total Liab5.7M6.3M18.6M69.7M64.8M68.0M
Total Current Assets17.2M66.9M232.8M136.0M61.8M51.8M
Common Stock4.1M1K2K3K2.7K2.6K
Net Debt(15.4M)(23.9M)(169.0M)(21.9M)(19.7M)(20.7M)
Net Invested Capital12.5M63.5M229.7M132.4M57.2M101.0M
Net Working Capital11.4M61.5M220.6M120.4M48.3M72.5M

DermTech Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what DermTech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense2.7M40K151K1.3M1.5M1.6M
Total Revenue3.4M5.9M11.8M14.5M15.3M16.1M
Gross Profit60K(96K)1.3M647K276K289.8K
Operating Income(17.6M)(35.3M)(77.4M)(118.2M)(103.7M)(98.6M)
Ebit(17.6M)(35.3M)(77.4M)(118.2M)(106.3M)(101.0M)
Research Development2.5M5.3M16.3M24.1M15.2M8.6M
Cost Of Revenue3.3M6.0M10.6M13.9M15.0M15.8M
Income Before Tax(19.7M)(35.2M)(78.3M)(116.7M)(100.9M)(95.8M)
Net Income(21.9M)(34.7M)(77.0M)(113.7M)(100.9M)(95.8M)
Income Tax Expense2.2M(526K)(1.4M)(3.0M)(2.7M)(2.5M)
Ebitda(18.0M)(34.8M)(76.3M)(118.3M)(106.5M)(101.2M)
Net Interest Income(2.7M)40K151K1.3M2.8M3.0M
Interest Income2.7M40K151K1.3M2.8M3.0M

DermTech Key Cash Accounts

Cash flow analysis captures how much money flows into and out of DermTech. It measures of how well DermTech is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money DermTech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money DermTech had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what DermTech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Change To Inventory5K(69K)(376K)(1.3M)753K790.7K
Change In Cash10.6M8.9M155.7M(98.7M)(41.0M)(39.0M)
Net Borrowings2.1M(9K)(171K)(137K)(123.3K)(117.1K)
Depreciation89K486K2.3M4.5M5.8M6.1M
Capital Expenditures210K1.8M2.7M3.3M902K913.0K
Net Income(19.7M)(35.2M)(78.3M)(116.7M)(100.9M)(95.8M)
Change To Netincome(838K)5.0M14.4M19.1M22.0M23.1M
End Period Cash Flow15.4M24.2M179.9M81.2M40.2M41.7M
Free Cash Flow(18.0M)(30.5M)(64.8M)(98.6M)(77.9M)(74.0M)
Other Non Cash Items414K(21K)1.9M585K672.8K706.4K

DermTech Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining DermTech's current stock value. Our valuation model uses many indicators to compare DermTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DermTech competition to find correlations between indicators driving DermTech's intrinsic value. More Info.
DermTech is one of the top stocks in number of employees category among related companies. It is one of the top stocks in beta category among related companies totaling about  0.01  of Beta per Number Of Employees. The ratio of Number Of Employees to Beta for DermTech is roughly  78.57 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DermTech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DermTech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DermTech's earnings, one of the primary drivers of an investment's value.

DermTech Systematic Risk

DermTech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DermTech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on DermTech correlated with the market. If Beta is less than 0 DermTech generally moves in the opposite direction as compared to the market. If DermTech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DermTech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DermTech is generally in the same direction as the market. If Beta > 1 DermTech moves generally in the same direction as, but more than the movement of the benchmark.

About DermTech Financials

What exactly are DermTech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include DermTech's income statement, its balance sheet, and the statement of cash flows. Potential DermTech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although DermTech investors may use each financial statement separately, they are all related. The changes in DermTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DermTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze DermTech Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as DermTech is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of DermTech has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if DermTech's financials are consistent with your investment objective using the following steps:
  • Review DermTech's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand DermTech's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare DermTech's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if DermTech's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

DermTech Thematic Clasifications

DermTech is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
HealthcareView
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in DermTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DermTech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of DermTech growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.012)

At this time, DermTech's Price Earnings To Growth Ratio is quite stable compared to the past year.

DermTech March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of DermTech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DermTech. We use our internally-developed statistical techniques to arrive at the intrinsic value of DermTech based on widely used predictive technical indicators. In general, we focus on analyzing DermTech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DermTech's daily price indicators and compare them against related drivers.
When determining whether DermTech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if DermTech Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Dermtech Stock. Highlighted below are key reports to facilitate an investment decision about Dermtech Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for DermTech Stock analysis

When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.09)
Revenue Per Share
0.469
Quarterly Revenue Growth
0.311
Return On Assets
(0.38)
Return On Equity
(1.06)
The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.